Troponin is a widely available biomarker for the diagnosis and prognostication of cardiac diseases. By using high-sensitivity assays, we demonstrated that cardiac troponin I was detectable in almost all (98.5%) patients and elevated in 9.3% of patients with atrial fibrillation. Determination of troponin levels with a high-sensitivity assay provided incremental discriminative information to the currently used CHA 2 DS 2 -VASc and HAS-BLED risk scores. Beyond clinical risk factors, an elevated level of troponin I identified patients with a doubled risk for stroke or systemic embolism and an up to 4.5-fold increased risk of vascular death. Troponin I measurements improved risk prediction substantially in patients with atrial fibrillation beyond currently used clinical risk scores. The availability of the cardiac troponin analysis is widespread and easily accessible and makes it a very attractive candidate for use to improve the prognostication of patients with atrial fibrillation in addition to the currently recommended clinical risk stratification models. See p 625.
Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Lipoprotein(a) is a low-density lipoprotein (LDL)-like particle with apolipoprotein B covalently linked to apolipoprotein(a). Lipoprotein(a) has been associated with cardiovascular disease via both mechanistic evidence of a proatherogenic or prothrombotic role and epidemiological and genetic studies in general populations. Several novel lipid therapeutic agents that lower lipoprotein(a) have recently entered phase III clinical trials, yet little is known about lipoprotein(a) and residual risk in the setting of potent statin therapy and low achieved LDL cholesterol. In this analysis from the JUPITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin), lipoprotein(a) was measured both at baseline and on-treatment in 9612 participants with elevated high-sensitivity C-reactive protein but normal LDL cholesterol who were randomly allocated to rosuvastatin or placebo. Lipoprotein(a) concentrations were stable over time, largely independent of other cardiovascular risk factors, and minimally effected by rosuvastatin. Lipoprotein(a) concentrations were greatest in blacks (median 60 nmol/L), then Asians (38 nmol/L), and then Hispanics (24 nmol/L) and whites (23 nmol/L). Among white participants, baseline lipoprotein(a) concentrations were associated with ≈20% higher relative risk of cardiovascular events per 1-SD (≈2.5-fold) increase, independent of LDL cholesterol or other risk factors. Similarly, on-statin lipoprotein (a) concentrations were associated with residual risk. The magnitude of relative risk reduction with rosuvastatin was similar among participants with high or low lipoprotein(a). Similar results were obtained when analyses included nonwhites. This study provides the first evidence to date that lipoprotein(a) concentrations are a determinant of residual risk after potent statin therapy. Future studies are needed to directly assess the impact of specifically lowering lipoprotein(a) on cardiovascular risk. See p 635.
Long-Term Coffee Consumption and Risk of Cardiovascular Disease: A Systematic Review and a Dose-Response Meta-Analysis of Prospective Cohort Studies
Coffee is one of the most widely consumed beverages around the world, and its association with cardiovascular disease has been investigated in numerous epidemiological studies. However, a key issue that remains to be resolved is the dose-response relationship of long-term coffee consumption with cardiovascular disease (CVD) risk, including incidence of coronary heart disease, stroke, and heart failure, and CVD mortality. In the current meta-analysis, we summarized results from 36 prospective cohort studies on coffee consumption and CVD risk with 1 279 804 study participants and 36 352 CVD cases. We found a nonlinear relationship of coffee consumption with CVD risk: Moderate coffee consumption was associated with lower risk of CVD, with the lowest CVD risk at 3 to 5 cups per day, and heavy coffee consumption was not associated with risk of CVD. Looking at outcomes separately, we also found nonlinear relationships of coffee consumption with coronary heart disease and stroke risks. The present study provides strong evidence that long-term heavy consumption of coffee is not associated with CVD risk and provides insight into the potential mechanism of the nonlinear relationship between coffee consumption and CVD risk. We believe that this report will be of significant interest to clinicians involved in the prevention and treatment of CVD. See p 643.
Survivin-Induced Abnormal Ploidy Contributes to Cystic Kidney and Aneurysm Formation
Autosomal-dominant polycystic kidney disease (ADPKD) is a ciliopathy characterized by the formation of kidney cysts and vascular aneurysms. Surprisingly, these balloon-like structures in the kidney and blood vessel are greatly associated with one another. Although abnormal cilia function in detecting urine flow will result in kidney cyst formation, inability of cilia to sense blood flow can induce vascular aneurysm. The formation of these balloon-like structures is independent from blood pressure but is tightly regulated by survivin expression. During repair resulting from any physiological perturbation or insult, a proper expression level of survivin is required to maintain the overall architectural structure of an organ. ADPKD with abnormal cilia function fails to maintain this architectural structure because of a low survivin expression, which induces asymmetrical cell division. As a result of this random expansion during cell division, an elongated architecture of a nephron or vasculature will no longer be achieved. It is therefore not surprising that it takes a long period of time Volume 129 ◼ Number 6 ◼ February 11, 2014
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to form such structural abnormalities as renal cysts and vascular aneurysms. Our studies also raise some questions: Can a similar mechanism also occur in other organs besides renal and vascular systems in ADPKD? In addition, can we use survivin or cell ploidity as a biomarker to indicate disease progression or severity in ADPKD? More specifically, we have used spectral karyotyping, which only requires 1 single cell from our ADPKD patients to confirm their cellular polyploidity throughout our studies. See p 660.
Bicuspid Aortic Cusp Fusion Morphology Alters Aortic Three-Dimensional Outflow Patterns, Wall Shear Stress, and Expression of Aortopathy
The findings of this study show that the presence of bicuspid aortic valve and type of cusp fusion pattern were accompanied by changes in systolic outflow as quantified by flow displacement, flow angles, and regional wall shear stress. Altered aortic hemodynamics were clearly associated with the predominant expression of the aortopathy phenotype (aortic region affected by dilatation) which was different for the right-left in comparison with the less common right-noncoronary cusp fusion morphology. These findings represent new insights regarding the current guidelines using maximal aortic diameter to influence timing and extent of surgical resection. The decision to resect aortic tissues in bicuspid aortic valve aortopathy is difficult, because the degree of aortic dilatation can be highly variable with respect to location on the aorta and the degree of enlargement. The findings of this study indicate that 4-dimensional flow MRI may be used to determine which regional areas of the aorta are most prone to developing aortopathy, and different aortic resection may be indicated in patients with right-left versus right-noncoronary fusion patterns. However, our data also indicate that hemodynamic alterations and the aortopathy phenotype can have variable patterns that could be important for clinical surgical management decisions for the individual patient. Novel metrics of aortic hemodynamics such as flow displacement may be capable of shaping these decisions with respect to the timing and extent of aortic replacement in this diverse group of patients with bicuspid aortic valve. See p 673.
Role of Hemostatic Factors on the Risk of Venous Thrombosis in People With Impaired Kidney Function
Why chronic kidney disease is associated with an increased risk of venous thrombosis is unclear. In this study, we hypothesized that impaired kidney function, estimated with either the Modification of Diet in Renal Disease equation or the Chronic Kidney Disease Epidemiology Collaboration equation, affects venous thrombosis risk via a concurrently raised procoagulant state. We found that moderately to severely decreased kidney function was associated with a 2.6-fold (95% confidence interval, 2.0-3.5) increased risk of venous thrombosis compared with normal kidney function. Several hemostatic factors showed a procoagulant shift with decreasing kidney function in control subjects, most notably factor VIII (on average, 41 IU/dL higher in moderately to severely decreased kidney function than in a normal kidney function) and von Willebrand factor (32 IU/dL higher). We showed that the increased risk of venous thrombosis in chronic kidney disease could not be explained by confounding or mediating factors such as body mass index, diabetes mellitus, hospitalization, or corticosteroid use. However, we found that factor VIII and von Willebrand factor fully explained the increased risk of venous thrombosis associated with impaired kidney function. Possibly, endothelial damage in patients with chronic kidney disease leads to increased factor VIII and von Willebrand factor levels and eventually to venous thrombosis. Our results indicate that chronic kidney disease is associated with a procoagulant state, for which patients may receive thromboprophylaxis when encountering a high-venous-thrombosis-risk situation. See p 683.
Endothelial Fate Mapping in Mice With Pulmonary Hypertension
Pulmonary endothelial injury triggers a reparative program, which in susceptible individuals is characterized by neointima formation, vascular narrowing, and the development of pulmonary arterial hypertension. The neointimal cells in human pathological plexiform lesions frequently coexpress smooth muscle α-actin and the endothelial von Willebrand antigen, creating a question about their cellular lineage of origin. Cellular fate-mapping studies in transgenic mice can be used to elucidate pathways of normal development or pathological disease. In this study, we intercrossed mice expressing transgenic vascular endothelial-cadherin Cre recombinase with mTomato/mGreen fluorescent protein double-fluorescent Cre reporter mice to achieve endothelial genetic lineage marking with membrane-targeted green fluorescent protein. In control mice, few endothelial lineage-marked cells lining the lumen of small pulmonary arteries exhibit expression of smooth muscle α-actin. Experimental pulmonary hypertension was induced in C57Bl/6 mice subjected to left pneumonectomy followed 1 week later by jugular vein injection of monocrotaline pyrrole. Concurrent with the development of pulmonary hypertension, endothelial lineage-marked green fluorescent protein-expressing cells are prominent in the neointima and demonstrate expression of smooth muscle α-actin and smooth muscle myosin heavy chain. Human pulmonary arterial hypertension neointimal and plexiform lesions contain cells that coexpress endothelial CD31 or von Willebrand antigen and smooth muscle α-actin. We conclude that neointimal cells in pulmonary hypertension include contributions from the endothelial genetic lineage with induced expression of smooth muscle α-actin and smooth muscle myosin heavy chain. Novel therapies for pulmonary arterial hypertension might include agents that promote the differentiated endothelial phenotype and suppress activation of smooth muscle gene expression in small pulmonary arteries after injury. See p 692.
